Tags : Depression

Pharma

FDA Reports Newly Added Guidelines for Drug and Device Makers

Shots: Opioid Abuse – Giving special priority to medication-assisted treatment(MAT) for patients to develop novel medicines for treatment of opioid use disorder encouraging drug sponsors to adapt new processes for evaluating effect and clinical benefit of MAT Depression– Plans to examine the onset of action of MDD for long-term or short- term usage; including those […]Read More